Global Chemo Crisis: US Turns to Indian Pharma as Domestic Shortages Hit Cancer Drug Supply Chains

Global Chemo Crisis: US Turns to Indian Pharma as Domestic Shortages Hit Cancer Drug Supply Chains​

The global supply chain for critical cancer medications is showing severe vulnerabilities. The United States has initiated a request to Indian drug manufacturers to help address a shortage of ifosfamide injection. This international focus comes at a worrying time, as India itself is struggling with domestic shortages of other essential chemotherapy drugs.

The two situations concern different medicines. The US request targets ifosfamide injection. Meanwhile, India’s internal challenge involves cisplatin and carboplatin, both platinum-based cancer treatments. The timing underscores a sharp industry-wide question: why are these older, widely used oncology drugs becoming vulnerable across multiple markets?

US Seeks Indian Manufacturers to Combat Ifosfamide Shortage​

The shortage of ifosfamide injection is linked primarily to manufacturing disruption. The U.S. Food and Drug Administration’s (FDA) India Office reached out through the Indian Drug Manufacturers’ Association (IDMA). They sought companies capable of supplying the drug in 1g and/or 3g strengths globally.

According to IDMA, the FDA was looking for manufacturers that currently produce or have the capability to manufacture ifosfamide injection for any market. Key players identified by both Mint and the Economic Times include Zydus, Cipla, Alkem Laboratories, and Aurobindo Pharma’s GLS, as these companies already possess the necessary molecular expertise and U.S. presence.

The global issue is not confined to American markets. A spokesperson from Baxter International noted that production had resumed but was operating at reduced capacity. This operational constraint led to limited supply through 2026 across various jurisdictions. The European Medicines Agency also reported a similar technical disruption affecting ifosfamide-containing cancer drugs in the EU into early 2027.

Root Causes of Cancer Drug Vulnerability Globally​

The fragility of these older injectable medicines highlights a critical industrial weakness. When production capacity is highly concentrated among a small number of specialized suppliers, one manufacturing interruption can quickly ripple across multiple countries and continents.

Furthermore, the vulnerability stems from three interconnected factors. First, sterile oncology injectables require extremely specialized facilities and strict regulatory controls. Second, many such drugs rely on costly raw materials. Third, older generic cancer treatments often operate on thin profit margins. This creates a profound policy tension between ensuring affordability for patients and maintaining the economic viability of production itself.

India Faces Chemo Crunch: Cisplatin and Carboplatin Supply Tighten​

The international call for aid comes just as domestic strain mounts in India. Indian patients are reportedly struggling to access cisplatin and carboplatin, platinum-based cancer drugs essential for treating ovarian, lung, and bladder cancers. Hospitals, especially government facilities, have reported tight supplies of these crucial medicines in recent weeks.

The core challenge here is the cost and availability of raw materials. India relies on imported platinum, and supply chains were negatively impacted by rising prices. Industry executives pointed to conflict in the Middle East as a contributing factor to manufacturing costs and supply-chain disruption. These challenges are compounded by existing price control mechanisms designed to protect patient affordability.

NPPA Intervention Raises Prices for Essential Oncology Medicines​

In response to the mounting domestic pressure, the National Pharmaceutical Pricing Authority (NPPA) took corrective action. On June 11, the authority invoked special provisions and increased the ceiling prices of cisplatin and carboplatin by a significant margin after receiving central government approval in public interest.

The pricing adjustments were substantial. The ceiling price for cisplatin was raised to ₹10.89 per ml from its previous rate of ₹7.26 per ml. Similarly, the ceiling price of carboplatin rose to ₹90.74 per ml from ₹60.49 per ml (excluding taxes). These increases are set as a one-time revision and will undergo review after six months, emphasizing the critical need for uninterrupted availability of these oncology essentials.

The situation underscores that while India holds a strong position in the global generics supply chain—which is why the U.S. turned to Indian manufacturers—domestic resilience remains fragile. The domestic shortage demonstrates that reliance on imported raw materials and rigid price controls can create acute supply stress, even when medicines are not brand new.